INTER-Regional COHORTE of Long Term Pancreatic Cancer Survivors

Pancreas Cancer Clinical Trial

— CaPaLong  

Official title:

INTER-Regional COHORTE of Long Term Pancreatic Cancer Survivors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04436679
• Other study ID #: 2019_29
• Secondary ID: 2019-A02001-56
• Status: Recruiting
• Start date: February 2, 2021
• Est. completion date: February 2025

Study information

• Verified date: April 2022
• Source: University Hospital, Lille
• Contact: Emmanuelle Leteurtre, MD,PhD
• Phone: 0320445556
• Email: emmanuelle.leteurtre[@]chru-lille.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study is particularly innovative as it will accurately analyze the microscopic characteristics of the stroma, tumor budding and mucin expression in adenocarcinomas of the pancreas, using a comparative approach of long-survivor/short-survival patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 144
• Est. completion date: February 2025
• Est. primary completion date: February 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients > 18 years of age at diagnosis

• Primary pancreatic cancer patients operated on in one of the 4 centres between 2001 and 2016

• Histopathological diagnosis of excreto-pancreatic adenocarcinoma of the pancreas, ductal adenocarcinoma or classical adenocarcinoma

• Tissue blocks (FFPE) available (tumour/healthy tissue)

• Affiliated to a social security scheme

Exclusion Criteria:

• Absence of Primary Cancer Tissue Blocks (PCTBs)

• Paraffin block fixed in Bouin or AFA

• Patient Refusal

• Pancreatic cancer not corresponding to a conventional excretopancreatic adenocarcinoma such as: carcinoma on intraductal papillary mucinous neoplasm, endocrine tumor/carcinoma, acinar cell carcinoma, ...).

• Patient died due to post-surgical complications (death within 30 days post-surgery).

• Surgical resection of macroscopic R2 type.

Related Conditions & MeSH terms

• Pancreas Cancer
• Pancreatic Adenocarcinoma
• Pancreatic Neoplasms

Locations

Country	Name	City	State
France	Hop Claude Huriez Chu Lille	Lille

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Lille

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relationship between known prognostic histological markers of pancreatic adenocarcinoma and patient survival.	Tissue analysis will be performed by conventional microscopy and will evaluate histological markers known in the literature to have a prognostic impact.	at 2 years
Secondary	Relationship between newly described histological markers for pancreatic adenocarcinoma and patient survival.	Immunohistochemistry tissue analysis. It will allow the evaluation of newly described histological markers for pancreatic adenocarcinoma, which could have a prognostic impact such as the immunophenotype of the inflammatory infiltrate, the expression of the mucins MUC1, MUC5AC, MUC4, MUC16, mesothelin, p53, Ki67 (MIB1) and markers of aggressive subtypes identified by transcriptome studies, in particular the basal-like molecular subtype.	at 2 years